Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | REN | P00797 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.46 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13450967 | 0.86 | ALDH1A1 (0.57) | ALDH1A1TRPM8LMNAL3MBTL1REN | |
| SCHEMBL2721394 | 0.82 | REN (0.69) | ALDH1A1LMNAPKMHDAC1HDAC6 | |
| SCHEMBL574486 | 0.81 | LMNA (0.61) | ALDH1A1LMNAPKMHDAC1HDAC6 | |
| SCHEMBL11429803 | 0.79 | LMNA (0.57) | ALDH1A1TRPM8LMNAL3MBTL1PKM | |
| SCHEMBL8079713 | 0.79 | NPC1 (0.48) | TRPM8LMNAL3MBTL1 | |
| SCHEMBL3662061 | 0.78 | LMNA (0.58) | ALDH1A1LMNAPKMHDAC1HDAC6 | |
| SCHEMBL27357692 | 0.78 | LTB4R2 (0.56) | ALDH1A1LMNAL3MBTL1HDAC1HDAC6 | |
| SCHEMBL14759143 | 0.77 | HPGD (0.48) | ALDH1A1TRPM8LMNAL3MBTL1 | |
| SCHEMBL1926269 | 0.77 | HDAC1 (0.73) | ALDH1A1LMNAL3MBTL1PKMHDAC1 | |
| SCHEMBL13256444 | 0.77 | RAB9A (0.71) | ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222338-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. | 2010-09-02 | — | — | US | disclosed |
| US-7745484-B2 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20070185144-A1 | Beta-secretase modulators and methods of use | AMGEN INC. (US) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222338-A1 | BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | ALDH1A1 2461/4885TRPM8 2819/4885LMNA 705/4885 |
| US-20070185144-A1 | Beta-secretase modulators and methods of use | BACE1, BACE2, APP | ALDH1A1 2461/4885TRPM8 2819/4885LMNA 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.